Columbus Circle Investors increased its position in Teligent, Inc. (NASDAQ:TLGT) by 54.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 276,472 shares of the company’s stock after buying an additional 97,642 shares during the quarter. Columbus Circle Investors owned 0.52% of Teligent worth $1,855,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Summit Creek Advisors LLC increased its stake in shares of Teligent by 15.6% in the third quarter. Summit Creek Advisors LLC now owns 795,853 shares of the company’s stock valued at $5,340,000 after buying an additional 107,245 shares during the period. Janus Henderson Group PLC acquired a new position in shares of Teligent in the second quarter valued at approximately $51,431,000. Argent Capital Management LLC acquired a new position in shares of Teligent in the second quarter valued at approximately $3,590,000. JPMorgan Chase & Co. increased its stake in shares of Teligent by 99.5% in the second quarter. JPMorgan Chase & Co. now owns 59,773 shares of the company’s stock valued at $547,000 after buying an additional 29,816 shares during the period. Finally, RK Capital Management LLC acquired a new position in shares of Teligent in the second quarter valued at approximately $4,581,000. 67.70% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/columbus-circle-investors-purchases-97642-shares-of-teligent-inc-tlgt/1719656.html.

Shares of Teligent, Inc. (NASDAQ TLGT) opened at $3.32 on Wednesday. The company has a debt-to-equity ratio of 2.23, a current ratio of 3.28 and a quick ratio of 2.71. Teligent, Inc. has a 52-week low of $2.82 and a 52-week high of $9.54.

Teligent (NASDAQ:TLGT) last released its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). The firm had revenue of $13.65 million for the quarter, compared to analyst estimates of $19.12 million. Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The business’s revenue for the quarter was down 15.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.01 EPS. equities research analysts expect that Teligent, Inc. will post -0.2 earnings per share for the current fiscal year.

Several research firms have recently issued reports on TLGT. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Teligent in a research note on Tuesday, August 8th. Roth Capital set a $9.00 price objective on Teligent and gave the company a “buy” rating in a research note on Wednesday, August 9th. BidaskClub downgraded Teligent from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. ValuEngine downgraded Teligent from a “hold” rating to a “sell” rating in a research note on Tuesday, July 25th. Finally, TheStreet downgraded Teligent from a “c-” rating to a “d+” rating in a research note on Wednesday, November 1st. Three analysts have rated the stock with a sell rating, two have issued a hold rating and one has issued a buy rating to the company’s stock. Teligent presently has a consensus rating of “Hold” and a consensus target price of $7.33.

Teligent Company Profile

Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.

Want to see what other hedge funds are holding TLGT?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teligent, Inc. (NASDAQ:TLGT).